Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jul 4, 2021

F ORM 4
---------------	--

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
Jayasuriya Anula	Lineage Cell Therapeutics, Inc. [ LCTX ]	(Check all applicable)
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X Director _ 10% Owner Officer (give title below) __ Other (specify below)
C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200	7/1/2021
(Street) CARLSBAD, CA 92008 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security 2. Trans. Date 2A. Deemed 3. Trans. Code 4. Securities Acquired (A) 5. Amount of Securities Beneficially Owned 6. 7. Nature (Instr. 3) Execution (Instr. 8) or Disposed of (D) Following Reported Transaction(s) Ownership of Indirect
Date, if any (Instr. 3, 4 and 5) (Instr. 3 and 4) Form: Beneficial
Direct (D) Ownership
or Indirect (Instr. 4)
(A) or (I) (Instr.
Code V Amount (D) Price 4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Stock Option (right to buy)	\$2.86	7/1/2021		A		50000		(1)	7/1/2031	Common Shares	50000	\$0	50000	D

Explanation of Responses:

(1) Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer.

Reporting Owners

		Relationships
	Reporting Owner Name / Address	Director	10% OwnerOfficerOther
Jayasuriya Anula
	C/O LINEAGE CELL THERAPEUTICS	X
	2173 SALK AVENUE, SUITE 200
CARLSBAD, CA 92008

Signatures

/s/ Grant Harbert, as Attorney-in-Fact 7/1/2021

\\Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.